ABT

Abbott Laboratories

ABT, USA

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

https://www.abbott.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

0.63

Next Payout:

Feb 13, 2026

Yield:

2.0784 %
ABT
stock
ABT

Abbott (ABT) stock price ticks higher as heart-device news lands ahead of earnings — what investors watch TechStock²

Read more →
ABT
stock
ABT

ABT.SW Abbott (SIX) CHF100.00 intraday: earnings 22 Jan 2026 could shift outlook Meyka

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$144.7492

Analyst Picks

Strong Buy

12

Buy

7

Hold

9

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

15.22

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

4.16

Low 1

High 3

Return on Equity (ROE)

-

Very Low

3.23 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

1.95 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

20.15 %

Low 5%

High 15%

Debt to Equity

-

Medium

0.65

Low 1

High 0.3

Investors

* Institutions hold a combined 66.65% of the total shares of Abbott Laboratories

1.

Vanguard Group Inc

(9.9285%)

since

2025/06/30

2.

BlackRock Inc

(8.1178%)

since

2025/06/30

3.

State Street Corp

(4.5019%)

since

2025/06/30

4.

Capital Research & Mgmt Co - Division 3

(3.4552%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(3.1408%)

since

2025/07/31

6.

Vanguard 500 Index Investor

(2.4745%)

since

2025/07/31

7.

Capital Research Global Investors

(2.3997%)

since

2025/06/30

8.

JPMorgan Chase & Co

(2.2583%)

since

2025/06/30

9.

Geode Capital Management, LLC

(2.2002%)

since

2025/06/30

10.

Morgan Stanley - Brokerage Accounts

(2.0228%)

since

2025/06/30

11.

Wellington Management Company LLP

(1.4393%)

since

2025/06/30

12.

NORGES BANK

(1.2784%)

since

2025/06/30

13.

Fidelity 500 Index

(1.2671%)

since

2025/07/31

14.

Bank of America Corp

(1.2465%)

since

2025/06/30

15.

Northern Trust Corp

(1.2089%)

since

2025/06/30

16.

SPDR® S&P 500® ETF

(1.2072%)

since

2025/08/31

17.

iShares Core S&P 500 ETF

(1.2029%)

since

2025/08/31

18.

American Funds Washington Mutual A

(1.0861%)

since

2025/06/30

19.

Capital Group Wash Mutual Invtrs Comp

(1.0861%)

since

2025/06/30

20.

Wells Fargo & Co

(0.9876%)

since

2025/06/30

21.

American Funds Invmt Co of Amer A

(0.9246%)

since

2025/06/30

22.

Capital Group Investment Co of Amer Comp

(0.9246%)

since

2025/06/30

23.

Vanguard Value Index Inv

(0.886%)

since

2025/07/31

24.

Goldman Sachs Group Inc

(0.8736%)

since

2025/06/30

25.

Massachusetts Financial Services Company

(0.8202%)

since

2025/06/30

26.

State Farm Mutual Automobile Ins Co

(0.7807%)

since

2025/06/30

27.

FMR Inc

(0.7793%)

since

2025/06/30

28.

Charles Schwab Investment Management Inc

(0.7571%)

since

2025/06/30

29.

Ameriprise Financial Inc

(0.747%)

since

2025/06/30

30.

UBS Asset Mgmt Americas Inc

(0.7325%)

since

2025/06/30

31.

The Health Care Select Sector SPDR® ETF

(0.6826%)

since

2025/08/31

32.

Capital Group American Mutual Comp

(0.6527%)

since

2025/06/30

33.

American Funds American Mutual A

(0.6527%)

since

2025/06/30

34.

American Funds Capital World Gr&Inc A

(0.61%)

since

2025/06/30

35.

Capital Group World Growth & Inc Cmp

(0.61%)

since

2025/06/30

36.

Vanguard Institutional Index I

(0.6043%)

since

2025/07/31

37.

Vanguard Dividend Appreciation ETF

(0.5371%)

since

2025/07/31

38.

American Funds Capital Income Bldr A

(0.534%)

since

2025/06/30

39.

State St S&P 500® Indx SL Cl III

(0.5336%)

since

2025/08/31

40.

American Funds American Balanced A

(0.4988%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

1.2

Latest Release

Date

2025-12-31

EPS Actual

EPS Estimate

1.5

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(8)
Dividend
Decent Dividend Payer(4)
Economic Moat
Wide Moat Company(7.3)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(3)
Momentum
Strong Momentum(6.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(7)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.